Genmab A/S Stock Nasdaq
Stocks
GMAB
US3723032062
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Nasdaq
04:00:00 12/09/2026 HKT
|
5-day change | 1st Jan Change | ||
| 32.47 USD | +0.74% |
|
-3.36% | +5.42% |
| Market Cap | 125B 19.41B 16.72B 15.83B 14.35B 26.92B 1,854B 27.06B 188B 72.31B 943B 72.89B 71.29B 2,981B | P/E 2026 * |
26.5x | P/E 2027 * | 18.6x |
|---|---|---|---|---|---|
| Enterprise Value | 144B 22.38B 19.29B 18.26B 16.55B 31.05B 2,138B 31.21B 217B 83.4B 1,088B 84.06B 82.22B 3,438B | EV / Sales 2026 * |
4.98x | EV / Sales 2027 * | 4.03x |
| Free-Float |
94.3% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| GMAB | Delayed | |
CBOE
| GMAB | Real-time | |
|
Boerse Muenchen
| GE91 | Real-time | |
|
Börse Stuttgart
| GE91 | Delayed | |
|
Tradegate
| GE91 | Real-time | |
|
Deutsche Boerse AG
| GE91 | Delayed |
Last Transcript : Genmab A/S
| 1 day | +0.74% | ||
| 1 week | -3.36% | ||
| Current month | -2.08% | ||
| 1 month | +3.34% | ||
| 3 months | +29.47% | ||
| 6 months | +22.21% | ||
| Current year | +5.42% |
| 1 week | 32.21 |  | 33.84 |
| 1 month | 31.14 | | 34.66 |
| Current year | 23.62 | | 35.43 |
| 1 year | 23.62 | | 35.43 |
| 3 years | 17.24 | | 38.8 |
| 5 years | 17.24 | | 47.5 |
| 10 years | 12.1 | | 49.07 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 01/06/2010 | |
Anthony Pagano
DFI | Director of Finance/CFO | 48 | 01/03/2020 |
Rayne Waller
CTO | Chief Tech/Sci/R&D Officer | - | 16/08/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 01/11/2003 | |
| Director/Board Member | 58 | 01/01/2015 | |
| Director/Board Member | 75 | 01/01/2015 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.74% | -3.36% | - | - | 19.41B | |
| -2.11% | -1.68% | +43.40% | +95.27% | 66.93B | |
| -0.23% | -4.45% | +32.50% | +75.75% | 61.97B | |
| +1.67% | +2.47% | -11.32% | +380.54% | 28.26B | |
| -1.05% | -4.43% | +28.84% | +10.59% | 24.59B | |
| +0.34% | -6.78% | -0.01% | -16.35% | 24.3B | |
| +0.43% | -3.37% | +16.22% | -17.99% | 19.41B | |
| -3.03% | -2.29% | +181.72% | +335.27% | 16.77B | |
| -1.94% | -4.94% | -8.15% | +483.69% | 14.18B | |
| +3.24% | -0.31% | -7.34% | +880.45% | 14B | |
| Average | -0.19% | -2.95% | +30.65% | +247.47% | 30.05B | |
| Weighted average by Cap. | -0.47% | -2.83% | +31.25% | +170.65% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 28.95B 4.49B 3.87B 3.67B 3.32B 6.24B 429B 6.27B 43.55B 16.75B 218B 16.88B 16.51B 690B | 33.72B 5.23B 4.51B 4.27B 3.87B 7.26B 500B 7.3B 50.72B 19.5B 254B 19.66B 19.23B 804B |
| Net income | 4.93B 765M 659M 624M 566M 1.06B 73.11B 1.07B 7.41B 2.85B 37.19B 2.87B 2.81B 118B | 7.16B 1.11B 958M 907M 822M 1.54B 106B 1.55B 10.78B 4.14B 54.05B 4.18B 4.09B 171B |
| Net Debt | 19.17B 2.98B 2.56B 2.43B 2.2B 4.13B 284B 4.15B 28.84B 11.09B 145B 11.18B 10.93B 457B | 11.01B 1.71B 1.47B 1.39B 1.26B 2.37B 163B 2.38B 16.56B 6.37B 83.07B 6.42B 6.28B 263B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/09/26 | US$32.47 | +0.74% | 1,394,020 |
| 10/09/26 | US$32.23 | -2.45% | 1,015,762 |
| 09/09/26 | US$33.04 | -1.46% | 2,125,948 |
| 08/09/26 | US$33.53 | -0.21% | 1,550,685 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GMAB Stock
- GMAB Stock
Select your edition
All financial news and data tailored to specific country editions
